PC
PACB icon

Polar Capital’s Pacific Biosciences PACB Stock Holding History

Polar Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$54M Buy
5,473,054
+1,723,054
+46% +$9.92M 0.4% 73
2020
Q2 		$12.9M Buy
3,750,000
+175,024
+5% +$596K 0.11% 157
2020
Q1 		$10.9M Buy
3,574,976
+3,074,976
+615% +$12.6M 0.12% 163
2019
Q4 		$2.57M Buy
+500,000
New +$2.54M 0.02% 253

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Polar Capital's PACB Position: Q3 2020 in Review

Polar Capital increased its Pacific Biosciences (PACB) stake by 46% in Q3 2020, buying an estimated $9.92M and bringing the position to 5,473,054 shares worth $54M. The position accounts for 0.4% of the portfolio, ranked #73.

Polar Capital first reported a position in PACB in Q4 2019 and has held it in 4 quarters since. 174 funds tracked by Wall St. Rank hold PACB as of Q3 2020.

  • Polar Capital held 5,473,054 shares of Pacific Biosciences worth $54M as of Q3 2020.
  • Polar Capital bought 1,723,054 Pacific Biosciences shares in Q3 2020, an estimated $9.92M.
  • Pacific Biosciences made up 0.4% of Polar Capital's portfolio in Q3 2020, its #73 holding.
  • Polar Capital first reported a position in Pacific Biosciences in Q4 2019 and has held it in 4 quarters since.
  • 174 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.